Compare AstraZeneca plc (AZN) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares MSCI China ETF — how do they compare? AstraZeneca plc trades at $168.75 (market cap $253.13B), while iShares MSCI China ETF trades at $54.24. The key difference: AstraZeneca plc pays a 1.92% dividend while iShares MSCI China ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| AZN | MCHI | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $66.99 |
52-Week Low | $137.44 | $50.48 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
MCHI trades at $52.53, down 1.13% on the day, with neutral technical signals from both moving averages and oscillators. The ETF shows mixed sentiment amid China's factory rebound driven by AI hardware exports and Beijing's $295 billion AI infrastructure plan. Recent news highlights China's tech sector momentum but also persistent geopolitical tensions with US restrictions on Chinese tech firms.
Outlook remains balanced with AI-driven growth potential offset by value trap risks and regulatory uncertainties. The ETF faces headwinds from US-China tech rivalry but benefits from China's massive domestic AI investment program. Investors should weigh sector-specific opportunities against broader macroeconomic and geopolitical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
